CD8A and central nervous system cancer: In the preclinical glioma model CT2-A, repeated administration of BVax and anti–PD-L1 allowed adoptively transferred CD8+ T cells to eradicate the tumor and prevent its regrowth upon reinjection in the opposite hemisphere in 50% of the treated mice after brain radiation and temozolomide treatment (GBM patient standard of care).